Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

Groningen, the Netherlands, September 30, 2014 – Mucosis B.V., a clinical stage biotechnology company developing novel vaccines for infectious diseases, will present updates on its research and development program at the Biotech in Europe Forum taking place in Basel, Switzerland 30 September through 01 October 2014.
Mucosis, which has recently announced several strategic partnerships including one with the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs, and another with China-based Changchun BCHT Biotechnology Co (BCHT), is advancing its lead product, SynGEM®, as a vaccine candidate for Respiratory Syncytial Virus (RSV).
“It’s an exciting time to be involved in novel vaccine development, given the urgent public health need to prevent infectious diseases in all corners of the world,” said Thomas Johnston, chief executive officer, Mucosis. “Based on our clinical-stage proprietary Mimopath® platform, Mucosis is well-positioned to deliver vaccines that can provide the first line of defense against infectious disease pathogens. We are pleased to have the opportunity to share updates on our pipeline with the investment community and also meet with potential partners at this meeting.”
Mr. Johnston will be presenting at 16:05 on September 30, and his presentation can be viewed on the Mucosis website www.mucosis.com from October 1, 2014.
Mr. Johnston will also be speaking on a panel discussion on vaccines, alongside representatives from Sanofi Pasteur MSD, Philimmune, Genocea Biosciences, VBI Vaccines, ABIVAX, Biomay, and Sofinnova Partners.

Leave a comment

Your email address will not be published.